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Abstract 
Background: The aim of this paper is to review multi-country evidence of private sector adherence to national regu-
lations, guidelines, and quality-assurance standards for malaria case management and to document current coverage 
of private sector engagement and support through ACTwatch outlet surveys implemented in 2015 and 2016.
Results: Over 76,168 outlets were screened, and approximately 6500 interviews were conducted (Cambodia, 
N = 1303; the Lao People’s Democratic Republic (PDR), N = 724; Myanmar, N = 4395; and Thailand, N = 74). There 
was diversity in the types of private sector outlets providing malaria treatment across countries, and the extent to 
which they were authorized to test and treat for malaria differed. Among outlets stocking at least one anti-malarial, 
public sector availability of the first-line treatment for uncomplicated Plasmodium falciparum or Plasmodium vivax 
malaria was >75%. In the anti-malarial stocking private sector, first-line treatment availability was variable (Cambo-
dia, 70.9%; the Lao PDR, 40.8%; Myanmar P. falciparum = 42.7%, P. vivax = 19.6%; Thailand P. falciparum = 19.6%, P. 
vivax = 73.3%), as was availability of second-line treatment (the Lao PDR, 74.9%; Thailand, 39.1%; Myanmar, 19.8%; and 
Cambodia, 0.7%). Treatment not in the National Treatment Guidelines (NTGs) was most common in Myanmar (35.8%) 
and Cambodia (34.0%), and was typically stocked by the informal sector. The majority of anti-malarials distributed in 
Cambodia and Myanmar were first-line P. falciparum or P. vivax treatments (90.3% and 77.1%, respectively), however, 
8.8% of the market share in Cambodia was treatment not in the NTGs (namely chloroquine) and 17.6% in Myanmar 
(namely oral artemisinin monotherapy). In the Lao PDR, approximately 9 in 10 anti-malarials distributed in the private 
sector were second-line treatments—typically locally manufactured chloroquine. In Cambodia, 90% of anti-malarials 
were distributed through outlets that had confirmatory testing available. Over half of all anti-malarial distribution was 
by outlets that did not have confirmatory testing available in the Lao PDR (54%) and Myanmar (59%). Availability of 
quality-assured rapid diagnostic tests (RDT) amongst the RDT-stocking public sector ranged from 99.3% in the Lao 
PDR to 80.1% in Cambodia. In Cambodia, the Lao PDR, and Myanmar, less than 50% of the private sector reportedly 
received engagement (access to subsidized commodities, supervision, training or caseload reporting), which was 
most common among private health facilities and pharmacies.
Conclusions: Findings from this multi-country study suggest that Cambodia, the Lao PDR, Myanmar, and Thailand 
are generally in alignment with national regulations, treatment guidelines, and quality-assurance standards. However, 
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Background
Malaria elimination is the goal of all countries in the 
Greater Mekong Subregion (GMS), with accelerated 
achievement a priority due to the emergence and spread 
of artemisinin drug resistant parasites. The World Health 
Organization (WHO) Strategy for Malaria Elimination in 
the GMS (2015–2030) sets a target of malaria elimination 
in all GMS countries by 2030 and Plasmodium falcipa-
rum malaria by 2025 [1]. Appropriate case management 
of all suspected malaria cases, including early confirma-
tory diagnosis and prompt treatment with effective, first-
line anti-malarial medicines, is essential to achieving the 
WHO elimination goals.
National programmes across the region have defined 
National Treatment Guidelines (NTG) stipulating the use 
of different first- and second-line treatments for uncom-
plicated and severe malaria (Table  1) for any Plasmo-
dium species infection. These guidelines vary by country 
in part due to the need to continually update guidelines 
based on the latest evidence regarding anti-malarial drug 
tolerance, therapeutic efficacy, and resistance [2].
Achieving universal coverage with quality-assured 
diagnostics and anti-malarials requires three channels 
of service delivery to be considered: public, private, and 
community-based [1]. It is acknowledged by the WHO 
that the optimal mix of these channels will vary between 
and within countries and in elimination settings, and 
that  the roles for each channel should be reviewed and 
defined, depending on the country situation and local 
conditions, to ensure optimal case management, surveil-
lance, and reporting in all areas.
In the GMS, the role of the private sector has been 
recognized as an important source of anti-malarial 
treatment in many countries, including Cambodia, 
Myanmar, and the Lao People’s Democratic Republic 
(PDR). Supply-side surveys have illustrated how most 
anti-malarial medicines are distributed through the 
private sector [3, 4], and these findings are comple-
mented by population-based surveys from these coun-
tries which illustrate that febrile patients commonly 
seek treatment in the private sector [5–7]. While the 
private sector is relevant across the region, the specific 
types of outlets that provide malaria testing and treat-
ment differs by country. In addition, national policies 
vary with respect to the specific providers and outlet 
types that are authorized to test for and treat malaria 
(Table  2). In the Lao PDR, all private for-profit health 
facilities and pharmacies are permitted to provide 
malaria testing and treatment, whereas in Cambo-
dia only private health facilities and registered phar-
macies in the Public–Private Mix (PPM) programme 
are authorized to test and treat. In grocery stores and 
general retailers, and among itinerant drug vendors, 
the sale of anti-malarials is prohibited by national 
important gaps persist in the private sector which pose a threat to national malaria control and elimination goals. 
Several options are discussed to help align the private sector anti-malarial market with national elimination strategies.
Keywords: Anti-malarial, Private sector, Greater Mekong Subregion (GMS), First-line, Second-line, Market share, 
Availability, RDT
Table 1 National Treatment Guidelines Cambodia, Lao PDR, Myanmar, and Thailand
a In late 2015, the Myanmar NTGs changed to AL + primaquine
b In late 2015, the Thailand malaria treatment guidelines changed in eight provinces to stipulate use of DHA PPQ, with a single dose of primaquine (30 mg) on day 1
Country Year First-line Pf First-line Pv First-line severe malaria Second-line
Cambodia 2014 Fixed-dose combination (FDC) artesunate-mefloquine 
(ASMQ) + primaquine or dihydroartemisinin-pipe-
raquine + primaquine (DHA-PPQ)
Artesunate Intravenous 
(IV)/Intramuscular (IM) or 
Artemether IV/IM
Pf/Pv: Quinine + doxycycline or 
tetracycline
Lao PDR 2013 Artemether–Lumefantrine (AL) + primaquine Artesunate IV/IM Pf: Quinine + doxycycline
Pv: Chloroquine
Severe: Quinine IV/IM
Myanmar 2012 AL or ASMQ or DHA 
PPQ + primaquinea
Chloroquine + pri-
maquine
Artesunate IV/IM Pf: Alternative first-line artemisinin-
based combination medicines or 
artesunate + either doxycycline, 
tetracycline, or clindamycin
Severe: Artemether IV/IM or Quinine 
IV/IM
Thailand 2014 ASMQ or DHA  PPQb + pri-
maquine
Chloroquine + pri-
maquine
Artesunate IV/IM Pf: Quinine + doxycycline, or artesu-
nate + doxycycline or clindamycin
Pv: Chloroquine
Severe: Quinine IV/IM
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authorities in Cambodia, the Lao PDR, and Thailand 
but not in Myanmar. In Thailand, the private sector is 
almost completely prohibited to provide anti-malarials 
or confirmatory testing, and only certain private hospi-
tals are permitted to provide testing and treatment on a 
case-by-case basis.
Although the private sector plays a significant role in 
malaria case management throughout these countries, 
several challenges have been noted with the performance 
of this sector. There may be a lack of knowledge among 
providers on where to refer patients with more severe 
conditions and limited provision of information to accom-
pany the sale of treatments [8]. Available treatments may 
be clinically inappropriate and/or administered in doses 
that are outside of the therapeutic range [8]. Private sec-
tor providers may also have little financial incentive to 
distribute first-line anti-malarials for treatment and will 
instead sell a wide variety of low-cost anti-malarials [9, 
10]. Similarly, while malaria rapid diagnostic tests (RDT) 
can accurately diagnose malaria and prevent the unnec-
essary use of artemisinin-based combination therapy 
(ACT), private sector providers may be reluctant to pro-
vide a confirmatory test given financial disincentives and a 
desire to profit through the sale of anti-malarial products 
[11, 12]. Moreover, providers, especially in the informal 
or unregulated sector, often have less training, including 
training on medicines that are not in the NTGs, which are 
subject to frequent changes given evolving drug resistance 
in the region [13]. These documented challenges with 
the private sector readiness and performance for malaria 
case management threaten recent elimination goals and 
strategies. To meet these elimination goals, it is impera-
tive that the private sector is in alignment with national 
regulations, guidelines, and quality-assurance standards 
for malaria case management.
Given the role and diversity of the private sector 
across different countries and challenges with its per-
formance, several efforts have been made to support 
and engage private sector providers to ensure high qual-
ity care or to prohibit this sector entirely from providing 
malaria case management services. This has included 
a PPM programme in Cambodia (since 2011) and the 
Lao PDR (since 2008) to regulate and license private 
for-profit facilities and pharmacies and to provide sub-
sidized malaria commodities, training, and supervision. 
In Myanmar, private sector strengthening through the 
Artemisinin Monotherapy Replacement (AMTR) Pro-
ject has been in place since 2012 to increase access to 
subsidized first-line treatments, including supportive 
interventions targeted at the informal private sector. 
In Thailand, the government banned the sale of anti-
malarials in the private sector in 1995 to control the 
spread of drug resistant parasites. To date, the compara-
tive performance of the different private sector anti-
malarial markets across these countries has yet to be 
investigated.
Table 2 Outlet type definitions
Outlet type Description Authorized to test and treat
Cambodia Lao PDR Myanmar Thailand
Public sector
 Public health facility Public health facilities include government health facilities as well as 
private not-for-profit facilities
× × × ×
 Community health 
worker
Community health workers (CHW) are community-based volunteers 
typically linked with government or non-government not-for-profit 
organizations and are equipped with anti-malarial treatment and 
malaria RDT. CHW receive formal training on malaria case management
× × × ×
Private sector
 Private health facility Private for-profit health laboratories, clinics, and hospitals that provide 
healthcare to the general public
× × ×
 Pharmacy Pharmacies are typically licensed and regulated by a national regulatory 
authority and are staffed by pharmacists and qualified health practition-
ers
× × ×
 Drug store Drug stalls in rural markets and shops that primarily sell medicines. These 
outlets are not guaranteed to be staffed by qualified health dispensers/
practitioners and are not licensed by a national regulatory authority. 
Drug stores are not found in Myanmar
 General retailer General retailers are grocery stores and village shops that sell fast-moving 
consumer goods, food, and provisions
×
 Itinerant drug vendor Mobile drug vendors found primarily in rural areas, typically working 
within the radius of their home or travelling to nearby villages to deliver 
medicines. They are not registered with any national regulatory author-
ity
×
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Given the popularity of private sector providers for 
health services, the private sector can be an asset for 
accelerating progress towards national malaria elimina-
tion goals. However, private providers operating outside 
of regulation, national guidelines, and quality-assurance 
standards pose a serious threat to elimination goals [14]. 
Market landscaping is essential in an elimination setting 
[15] as it provides insights into the breadth and quality 
of private sector diagnosis, treatment, and reporting and 
identifies gaps and challenges in each country context. 
Information provided through a market landscape can 
help prioritize the specific outlets to target and identify 
the extent to which outlets are operating in accordance 
with the current regulatory environment. Evidence can 
be adapted to create strategies for engagement with the 
private sector within each country.
The aim of this paper is to review multi-country evi-
dence of private sector adherence to national regula-
tions, guidelines, and quality-assurance standards for 
malaria case management and to document current 
coverage of private sector engagement and support. This 
information can be used to target appropriate strategies 
designed to ensure private provider alignment with and 
contributions to national malaria control and elimina-
tion goals.
Methods
ACTwatch was launched in 2008 by Population Ser-
vices International (PSI) with support from the Bill and 
Melinda Gates Foundation. Details about the ACTwatch 
project and methodology have been published elsewhere 
[16, 17]. The goal of the project is to generate timely, rel-
evant, and high quality evidence about anti-malarial and 
diagnostic markets for policy makers, donors, and imple-
menting organizations. As of 2016, ACTwatch had gath-
ered data from a total of 12 malaria endemic countries 
in sub-Saharan Africa and the GMS. This paper presents 
data from outlet surveys in four GMS countries collected 
in 2015 and 2016.
Design and sampling
The ACTwatch outlet surveys were nationally-represent-
ative or sub-national surveys conducted among a sample 
of outlets stocking anti-malarial medicines and diagnos-
tics. All categories of outlets with the potential to stock 
anti-malarials in both the public and private sectors were 
included in the study. In the public sector, this included 
government health facilities (hospitals, centres, clin-
ics, and posts) and community health workers (CHW). 
Outlets sampled in the private sector included private 
for-profit health facilities (hospitals, centres, and clin-
ics), pharmacies, drug stores, general retailers, and itiner-
ant drug vendors (mobile vendors without a fixed service 
delivery point). Drug stores were not present in Myan-
mar and thus not represented as an outlet category. In 
Myanmar, permission was not received to include public 
health facilities, so these were excluded from the study.
Probability proportional to size (PPS) sampling was 
used to select administrative units for the surveys using 
each country’s national population sampling frames. 
Administrative units were clusters that typically had a 
population size of 10,000–15,000 inhabitants. As lists of 
all potentially eligible outlets were not routinely available, 
an outlet census was used to identify outlets for inclu-
sion in the survey. To identify outlets, interviewers would 
walk systematically through each of the selected clus-
ters looking for relevant outlets. Lists of registered out-
lets, such as public health facilities or pharmacies, were 
obtained prior to the data collection and used to help 
identify outlets. Local maps were also used to identify the 
catchment area of each selected cluster within a country. 
To identify itinerant drug vendors, congregation points 
or locations were identified using key informant inter-
views. These providers were approached by interviewers 
and asked if they had already participated in the survey 
to avoid duplication. Within each selected cluster, all 
outlet types with the potential to provide anti-malarials 
to consumers were screened. Outlets were eligible for a 
provider interview and malaria product audit if they met 
at least one of three study criteria: (1) one or more anti-
malarials reportedly in stock on the day of the survey; (2) 
one or more anti-malarials reportedly in stock within the 
3 months preceding the survey; and/or (3) malaria RDT 
in stock or malaria microscopy available on the day of the 
survey. The sampling strategy and stratification is sum-
marized in Table 3.
In the Lao PDR and Thailand, boundaries for the out-
let census were extended to higher administrative units 
to cover a larger area for key outlets or areas. In the Lao 
PDR, this included oversampling of pharmacies and 
private for-profit health facilities at the district level. In 
Thailand, the geographic area for sampling outlets was 
extended to the district level for districts with an interna-
tional border. This booster sampling strategy was used to 
expand the census and screening of pharmacies.
Myanmar had four geopolitical zones that were used 
as research domains. Since 2012, yearly sub-national 
surveys had been conducted in the Central and Eastern 
parts of the country as a means to monitor the AMTR 
project. The Eastern part of the country had been previ-
ously described as the AMTR project intervention area, 
given that several supportive interventions have been 
implemented in this part of the country [3, 18]. The Cen-
tral domain had been described as the ‘Comparison’ area 
to observed differences between this area and the East-
ern domain, where AMTR activities had been in place. 
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Cambodia and Thailand had two research domains, and 
the study was stratified to deliver estimates for relevant 
research domains. Both Thailand and the Lao PDR were 
sub-national surveys, while Cambodia and Myanmar 
were nationally representative.
The study was designed to generate estimates for 
key market indicators within each domain. Minimum 
sample size requirements were calculated to estimate, 
with  ±10% precision, the following indicators: (1) the 
proportion of private sector outlets with ACT medicine 
available, among outlets with anti-malarial(s) in stock on 
the day of the survey; and (2) proportion of outlets with 
malaria blood testing (RDT or microscopy) available, 
among outlets with anti-malarial(s) in stock on the day 
of the survey or within the past 3 months. The number 
of study clusters was calculated for each research domain 
based on the required number of anti-malarial stocking 
outlets and assumptions about the number of anti-malar-
ial stocking outlets per cluster. Sample size requirements 
for follow-up surveys were calculated using information 
from previous survey rounds where available.
Data collection periods varied by country and over 
time but were typically implemented during the peak 
malaria transmission season for each country and lasted 
approximately 6  weeks, with the exception of Myanmar 
which took over 4 months.
Training and data collection
Interviewer training consisted of standardized classroom 
presentations and exercises as well as a field exercise. 
Additional training was provided for supervisors and 
quality-controllers focused on field monitoring, verifica-
tion visits, and census procedures. Data collection teams 
were provided with a list of selected clusters and offi-
cial maps that illustrated administrative boundaries. In 
each selected cluster, fieldworkers conducted a full enu-
meration of all outlets that had the potential to provide 
anti-malarials. This included enumeration of outlets with 
a physical location, as well as identification of CHW and 
itinerant drug vendors using local informants.
Quality control measures implemented during data col-
lection included questionnaire review by supervisors and 
interview verification visits conducted by quality con-
trollers to between 10 and 20% of all outlets. Up to three 
visits were made to all outlets to complete the screening 
process, audit, and provider interview as needed.
As previously mentioned, a series of screening ques-
tions were administered at all outlets to determine eli-
gibility for the survey. Following informed consent 
procedures, an audit of all available anti-malarial medi-
cines and RDT was conducted. In addition to the prod-
uct audit, a series of questions were administered to the 
senior-most provider regarding malaria case manage-
ment knowledge and practices. Questions were also 
administered to providers to measure the extent to which 
they reportedly received supervision, training on NTG or 
malaria diagnostics, access to subsidized anti-malarials, 
and caseload reporting. Questions regarding access to 
subsidized anti-malarials and RDT were not adminis-
tered in Myanmar.
All surveys were paper-based with the exception of 
Cambodia, where data were collected using Android 
phones and forms created using DroidDB (© SYWARE, 
Inc., Cambridge, MA, USA). Interviews were conducted 
in the local language using questionnaires that were 
translated from English to the local language and back to 
English to confirm translations.
Data analysis
Double data entry was conducted using Microsoft 
Access (Microsoft Corporation, Redmond, WA, USA) 
with built-in range and consistency checks. Data were 
analysed across survey rounds using Stata (StataCorp 
College Station, TX). Sampling weights were calculated 
Table 3 Summary of sampling procedures across the study countries
Cambodia Lao PDR Myanmar Thailand
Dates of data 
collection
August 17th to October 1st, 2015 November 18th to 
December 29th, 2015
August 18th, 2015, to 
January 4th, 2016
February 9th to March 
22nd, 2016
Stratification National, two domains based on the WHO evi-
dence about artemisinin resistance to define a 
3-tier stratification [45]:
Tier 1 provinces (prioritized for immediate 
multifaceted response to contain or eliminate 
resistance)
Tier 2 provinces (prioritized for intensified malaria 
control to reduce transmission and/or limit 
the risk of emergence or spread of resistant 
parasites)
Sub-national, five 
southern provinces
National, four geographic 
domains:
Eastern domain
Central domain
Western domain
Coastal domain
Sub-national, two geo-
graphic domains:
Thai–Cambodia border 
areas
Thai–Myanmar border 
areas
Number of 
clusters
160 Communes 77 Village groups 808 Wards and village 
tracts
194 Sub-districts
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as the inverse of the probability of cluster selection. All 
point estimates were weighted using survey settings and 
all standard errors calculated taking account of the clus-
tered and stratified sampling strategy.
Standard indicators were constructed according to 
definitions applied across the ACTwatch project and 
have been described in detail elsewhere [17, 19]. Briefly, 
anti-malarials identified during the outlet drug audit 
were classified as treatments found in the NTGs or not, 
and within the NTGs as first-line or second-line treat-
ment for P. falciparum and P. vivax malaria. Drug audit 
information used for the classification included active 
ingredients, formulation, and strengths. Official NTGs 
in use at the time of the survey were used for the classifi-
cation. Availability of NTG treatments at the outlet level 
was defined as availability of any component of what 
may be a multi-drug regimen. However, when one of the 
drugs was not an anti-malarial (e.g. antibiotics), the anti-
malarial was only classified as a medicine in the NTGs if 
the partner antibiotic was available as well. The rationale 
for this classification is that if the anti-malarial medi-
cine was present without the antibiotic, the anti-malarial 
could not be administered according to the NTGs. First-
line and second-line treatment availability, and treat-
ments not in the NTGs, were restricted to those outlets 
that had anti-malarials in stock.
RDT were classified as quality-assured or non quality-
assured. Quality-assured RDT were RDT that were in 
compliance with the Global Fund Quality Assurance 
Policy on the Global Fund list of approved RDT products 
for procurement. The product catalogue number (PCN) 
was used to identify products on the Global Fund list of 
approved products. Availability of quality-assured RDT 
and non quality-assured RDT was restricted to outlets 
with an RDT in stock.
Anti-malarial market composition was defined as the 
proportion of outlets of each type, among outlets with anti-
malarials in stock on the day of the survey. Market share, 
or the relative distribution of anti-malarials to individual 
consumers recorded in the drug audit, was standardized 
to allow meaningful comparisons between anti-malarials 
with different treatment courses and different formula-
tions. The adult equivalent treatment dose (AETD) was 
defined as the amount of active ingredient required to 
treat an adult weighing 60  kg according to WHO treat-
ment guidelines [2]. Provider reports on the amount of 
the drug sold or distributed during the week preceding the 
survey were used to calculate volumes according to type 
of anti-malarial. The volume of each drug was calculated 
as the number of AETDs that were reported to have been 
sold/distributed during the week preceding the survey. 
Measures of volume included all dosage forms to provide a 
complete assessment of anti-malarial market share.
Results
In total, 76,168 outlets were screened for availability of 
anti-malarials and malaria diagnostics during the 2015 
and 2016 outlet surveys: Cambodia (N  =  26,664), the 
Lao PDR (N = 7586), Myanmar (N = 28,267) and Thai-
land (N =  13,651). For all surveys, the majority of out-
lets screened and with completed interviews were private 
sector outlets. Approximately 6500 full interviews were 
conducted (Cambodia, N = 1303; the Lao PDR, N = 724; 
Myanmar, N = 4395; and Thailand, N = 74) where a total 
of 11,437 anti-malarials and 4043 RDT were audited. 
Refer to Table 4 for a full breakdown of the screening and 
audit results for each country by sector.
Across the facility types, availability of at least one anti-
malarial among all screened outlets varied. Anti-malari-
als were commonly available in public health facilities in 
Table 4 Results of the outlet census and AM/RDT product audit (N)
a Outlets are eligible for the outlet survey if they either (1) have anti-malarials currently in stock at the time of the interview, (2) have stocked anti-malarials in the past 
3 months, or (3) currently stock malaria microscopy or malaria RDT
b In Myanmar, public health facilities were not included in the study. The numbers in this table reflect the results of the outlet census and audit of CHW in Myanmar
Cambodia Lao PDR Myanmar Thailand
Public Private Public Private Publicb Private Public Private
Screened 604 26,060 558 7028 2737 25,530 355 13,296
Eligiblea 558 750 258 467 1449 2948 79 25
Interviewed 557 746 258 466 1463 2932 49 25
Anti-malarial(s) in stock 467 391 236 394 1263 2596 72 19
Anti-malarial(s) out of stock, in 
stock in the past 3 months
75 179 19 30 119 294 0 1
Malaria testing available 15 176 3 42 81 42 7 5
Anti-malarials audited 759 531 773 217 4227 4642 247 41
Malaria RDT audited 605 592 893 266 1188 447 44 8
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Cambodia (77.9%), the Lao PDR (97.8%) and in Thailand 
(94.9%). Private sector availability was lower, and most 
common among private for-profit facilities in Cambo-
dia (31.0%), the Lao PDR (36.2%) and Myanmar (50.4%). 
In the Lao PDR, 70.6% of pharmacies had at least one 
anti-malarial in stock. Across other private sector out-
let types, anti-malarials were less commonly available 
(<20%) (Additional file 1).
Market composition
Figure  1 shows that, in terms of absolute number of 
places where anti-malarial medicines were available, 
there was considerable diversity in the types of out-
lets providing malaria treatment across countries. In 
Cambodia, the private sector market composition was 
comprised primarily of private for-profit facilities and 
itinerant drug vendors. In the Lao PDR and Thailand, 
the private sector service delivery points were typically 
pharmacies. In Myanmar, the private sector composi-
tion comprised primarily of general retailers, but itiner-
ant drug vendors and pharmacies were also common. In 
the public sector, across Cambodia, the Lao PDR, and 
Myanmar, CHW composed just over 40% of the mar-
ket composition, and findings were similar between 
these three countries. In Thailand, public health facili-
ties were the most common type of outlet stocking anti-
malarials (87.6%), but in the Lao PDR and Cambodia, 
public health facilities were less than 25% of the anti-
malarial service delivery points.
The outer pie chart in Fig. 1 illustrates outlets that are 
authorized to test for and treat malaria, according to 
national policy. All of the private sector outlets in Thai-
land were not authorized to test for or treat malaria. In 
Cambodia, half of the private sector anti-malarial market 
composition consisted of outlets that were not author-
ized to test for or treat malaria, and in the Lao PDR this 
included one in four private sector anti-malarial stocking 
outlets. In contrast, all private sector outlets in Myanmar 
were authorized to test for and treat malaria.
Anti-malarial availability
Availability of first-line, second-line, and treatment not 
indicated in the NTGs among anti-malarial stocking 
outlets is shown in Fig. 2. Treatment categories for each 
Thailand, N=87
Lao PDR, N=402Cambodia, N=858 
Public Health Facility
Community Health Worker
Private Health Facility
Pharmacy
Drug Store
General Retailer
Itinerant Drug Vendor
Myanmar*, N=3,859
Authorised to test and treat if
part of the PPM programme
Not authorised to test or treat
*In Myanmar, this excludes public health facilities, which were 
  not included in the study
Outlet pie chart legend 
Inner pie chart legend 
Fig. 1 Anti-malarial market composition
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country are defined in Table 2. Availability of NTG treat-
ments at the outlet level were defined as availability of 
any component of what may be a multi-drug regimen 
according to each country’s recommended guidelines.
Public sector
Among outlets stocking at least one anti-malarial in the 
public sector, availability of any component of the first-
line treatment for uncomplicated P. falciparum or P. 
vivax malaria was greater than 85% and highest in Cam-
bodia, where there was almost universal coverage (99%). 
One exception to this was found among CHW in Myan-
mar, where slightly less than three-quarters of these out-
lets had any component of the first-line treatment for P. 
vivax available (74.5%). Availability of any component of 
the first-line treatment for severe malaria was less than 
5% of the anti-malarial stocking public sector in Cam-
bodia, the Lao PDR, and Myanmar. Stocking rates of 
the first-line treatment for severe malaria were slightly 
higher in Thailand’s public sector (18.1%).
In the anti-malarial stocking public sector, availability 
of any component of the second-line treatment was low 
in Cambodia (2.5%), the Lao PDR (12%), and Myanmar 
(12%). In Thailand, around one in three public sector 
outlets were stocking any component of the second-line 
treatment (31.7%). Availability of treatment not in the 
NTGs was generally less than 5% across Cambodia, the 
Lao PDR, and Myanmar’s public sector. In Thailand, 
18.2% of the anti-malarial stocking public sector had 
treatments that were not in the NTGs.
Private sector
Among outlets stocking at least one anti-malarial in the 
private sector, availability of any component of the first-
line treatment for uncomplicated P. falciparum or P. 
vivax malaria was variable across countries and lower 
than the public sector. In Cambodia, availability of the 
first-line treatment for P. falciparum or P. vivax (ACT) 
was 70.9%, and in the Lao PDR, less than half of the anti-
malarial stocking outlets had the first-line P. falciparum 
or P. vivax treatment (ACT) in stock (40.8%). In Myan-
mar and Thailand, less than half of the private sector had 
any component of P. falciparum treatment (ACT and/or 
primaquine) (42.7 and 19.6% respectively). Availability of 
any component of P. vivax treatment (chloroquine and/
or primaquine) was higher in these countries (56.2 and 
73.3%, respectively). Availability of any component of 
the first-line treatment for severe malaria was generally 
less than 5% of the anti-malarial stocking private sector 
across all countries but was slightly higher in Thailand 
(10.3%).
In the private sector, across all countries, availability 
of any component of the second-line treatment among 
anti-malarial stocking outlets was variable and highest 
in the Lao PDR (74.9%) followed by Thailand (39.1%). 
In these countries, availability of second-line treatment 
was greater than availability of the first-line treatment 
for uncomplicated malaria. In Myanmar, second-line 
treatment was available in one in five anti-malarial stock-
ing private sector outlets (19.8%) and rarely present in 
Cambodia (0.7%). The types of second-line treatment 
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Fig. 2 Anti-malarial availability in the public and private sectors
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medicines that were available were different across coun-
tries. In the Lao PDR, this was predominately second-
line treatment for P. vivax malaria (chloroquine tablets, 
branded as  Maraquin®) and Maraquin was included in 
the national list of registered medicines. In Myanmar, 
this was second-line treatment for severe malaria (qui-
nine and artemether liquid injections), and in Thailand, 
this was second-line treatment for P. falciparum malaria 
(quinine + doxycycline tablets).
Approximately one in three private sector outlets in 
Cambodia (34.0%) and Myanmar (35.8%) stocked medi-
cines that were not included in the NTGs. In Cambo-
dia, these medicines were most commonly chloroquine 
tablets, artemisinin piperaquine tablets, and non-FDC 
artesunate mefloquine tablets. In Myanmar, these medi-
cines were commonly oral artemisinin monotherapy. See 
Additional file  2 for a comprehensive list of all audited 
anti-malarials that were not included in the NTGs.
Types of private sector outlets stocking non‑first‑line 
treatments
Table  5 illustrates the availability of any component of 
the second-line treatment and treatment not included 
in the NTGs among anti-malarial stocking private sec-
tor outlet types. Availability of second-line treatment 
was most common among pharmacies (the Lao PDR, 
72.4%; Myanmar, 27.2%; and Thailand, 28.1%) and itiner-
ant drug vendors (the Lao PDR, 57.6%; Myanmar, 46.9%). 
Private for-profit facilities were also found to commonly 
stock any component of the second-line treatment in 
some countries (the Lao PDR, 49.3%; Thailand, 70.0%). 
Availability of private sector second-line treatment was 
observed across all outlets in the Lao PDR and was rarely 
found in Cambodia’s private sector.
Availability of treatment not in the NTGs was most 
common among itinerant drug vendors (Cambodia, 
48.4%; the Lao PDR, 57.6%; Myanmar, 29.5%) and general 
retailers (Cambodia, 100%; Myanmar, 43.0%). Availabil-
ity of treatment not in the NTGs was common (>20%) 
across all private sector outlet types in Myanmar.
Anti-malarial market share
Figure  3 shows the market share of different catego-
ries of anti-malarials sold or distributed in the 7  days 
prior to the survey. The private sector played a larger 
role than the public sector in the distribution of anti-
malarials. The majority of anti-malarials distributed in 
Cambodia and Myanmar were first-line P. falciparum 
or P. vivax treatments (90.3 and 77.1% respectively). 
In the Lao PDR, only 37% of the anti-malarial mar-
ket share was first-line treatment for P. falciparum or 
P. vivax malaria. In all three countries, public sector 
market share was dominated by first-line P. falciparum 
or P. vivax treatment. In the private sector, the anti-
malarials distributed included second-line treatment 
and treatment not in the NTGs. In the private sector 
in Cambodia and Myanmar, 8.8 and 17.6% of national 
anti-malarial market share, respectively, were treat-
ment not in the NTGs. In the Lao PDR, 59.0% of 
national market share was private sector second-line 
treatment. Approximately 9 in 10 anti-malarials dis-
tributed in the Lao PDR’s private sector were second-
line treatments.
Private-sector anti-malarials not included in national 
treatment guidelines
Additional file 2 includes a list of all audited anti-malar-
ials that were not indicated in NTGs for each of the 
study countries. Product characteristics such as generic 
name, formulation, brand name, manufacturer, country 
of manufacturer, registration status, number of prod-
ucts audited, and outlet type are described. There were 
9 unique products audited in Cambodia, 4 in the Lao 
PDR, 26 in Myanmar, and 3 in Thailand. All anti-malari-
als except for 2  (Mephaquin® manufactured by Mepha in 
Switzerland and  Malanil® manufactured by Glaxosmith-
kline in Canada) were manufactured in Asian countries 
(China, India, the Lao PDR, Myanmar, Pakistan, Thai-
land, Vietnam).
In Cambodia, all audited anti-malarials that were not 
indicated in the NTGs were either artemisinin pipe-
raquine tablets (n  =  31), artesunate tablets (n  =  1), 
chloroquine tablets (n  =  67), or non-FDC artesunate 
mefloquine tablets (n  =  27). No audited products in 
Cambodia were manufactured locally, and only 1 was 
included in the national list of registered medicines 
(chloroquine tablets manufactured by Acdhon). In the 
Lao PDR, the majority of products audited that were 
not in the Lao PDR NTGs included chloroquine injec-
tions (n  =  45) and syrups (n  =  4). The chloroquine 
injection audited was  Malacin® and was included in the 
national list of registered medicines, while the chloro-
quine syrup was branded  Chloquine® and, although 
manufactured locally in the Lao PDR, was not included 
in the list of registered medicines. In Myanmar, most 
products audited were artemether (n = 57), artesunate 
(n  =  891), and SP tablets (n  =  66). Of the artesunate 
tablets audited, 88% (n  =  784) were manufactured by 
 Mediplantex® in Vietnam. Several products (unbranded 
artesunate and mefloquine tablets, and SP  Pyrixine®) 
were manufactured locally by Myanmar/Tatmadaw 
Pharmaceutical Factory. None of these aforementioned 
products found in Myanmar were included in the 
national list of registered medicines. There were only 3 
products audited in Thailand that were not included in 
the NTGs.
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Malaria confirmatory testing availability and types of RDT 
products
Availability of any test among the anti-malarial stock-
ing public health facilities was greater than 90% across 
Cambodia (98.8%), the Lao PDR (90.8%) and Thailand 
(94.7%). Availability among anti-malarial stocking CHW 
was greater than 80% in Cambodia (91.4%), the Lao PDR 
(81.8%) and Myanmar (81.6%). The private sector ranged 
from 87.2% of anti-malarial stocking private for-profit 
facilities in Cambodia, 78.6% in the Lao PDR, 58.0% in 
Myanmar and 91.2% in Thailand. Among anti-malarial 
stocking pharmacies, availability ranged from 74.8% in 
Table 5 Percentage of anti-malarial stocking private sector outlets with non-first-line anti-malarials available
a  Drug stores do not exist in Myanmar
Private for-profit health facility
% (CI)
Pharmacy
% (CI)
Drug store
% (CI)
General retailer
% (CI)
Itinerant drug vendor
% (CI)
Private sector total
% (CI)
Cambodia N = 186 N = 45 N = 22 N = 29 N = 109 N = 391
 Second-line 0.3 0.0 6.8 0.0 0.6 0.7
(0.1, 2.0) – (1.9, 21.4) – (0.1, 3.7) (0.2, 2.2)
 Not in NTGs 12.8 16.3 45.3 100.0 48.4 34.0
(7.8, 20.4) (9.0, 27.7) (26.1, 66.1) – (38.2, 58.6) (26.4, 42.5)
Lao PDR N = 56 N = 309 N = 3 N = 23 N = 3 N = 394
 Second-line 49.3 72.4 100.0 96.9 57.6 74.9
(33.7, 65.0) (64.8, 78.9) – (83.0, 99.5) (40.9, 72.8) (68.6, 80.3)
 Not in NTGs 11.1 15.3 0.0 0.0 57.6 12.8
(5.4, 21.5) (10.4, 21.9) – – (40.9, 72.8) (8.9, 18.2)
Myanmar N = 314 N = 522 N/Aa N = 1341 N = 419 N = 2596
 Second-line 15.6 27.2 – 6.2 46.9 19.8
(9.2, 21.9) (20.8, 33.5) (3.4, 9.0) (40.7, 53.1) (16.3, 23.3)
 Not in NTGs 20.3 43.0 – 43.0 29.5 35.8
(13.8, 26.8) (35.6, 50.4) (36.7, 49.3) (23.0, 36.0) (31.6, 39.9)
Thailand N = 9 N = 10 N = 0 N = 0 N = 0 N = 19
 Second-line 70.0 28.1 – – – 39.1
(23.8, 94.6) (10.5, 56.7) – – – (19.6, 62.9)
 Not in NTGs 48.1 0.0 – – – 12.6
(13.7, 84.4) – – – – (3.2, 38.6)
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Cambodia, 56.6% in the Lao PDR, 15.6% in Myanmar. 
Availability was 17.9% among anti-malarial stocking itin-
erant drug vendors in Myanmar and less than 5% of gen-
eral retailers in the Lao PDR and Myanmar (Fig. 4).
Among outlets stocking any RDT, availability of malaria 
RDT with and without Global Fund Quality Assurance 
status and according to parasite species detection among 
RDT-stocking outlets is shown in Fig.  5. Amongst the 
RDT-stocking public sector, availability of quality-assured 
RDT ranged from 99.3% in the Lao PDR to 80.1% in Cam-
bodia. Public sector availability of non quality-assured 
RDT was 38.1% in Cambodia, 20.8% in Thailand, and was 
negligible or non-existent across the other countries.
Amongst the RDT-stocking private sector, 100% of pri-
vate facilities in Thailand had quality-assured RDT in stock 
and almost all private facilities in the Lao PDR (94%). In 
Cambodia and Myanmar, 3 in 4 private sector RDT-stock-
ing facilities had quality-assured RDT available. Private sec-
tor availability of non quality-assured RDT was observed 
in 25.7% of facilities in Cambodia and 17.2% in Myanmar. 
Private sector availability of non quality-assured RDT was 
negligible or non-existent in the Lao PDR and Thailand.
Almost all RDT audited in the four countries could 
detect P. falciparum and either P. vivax (Pf/Pv) or other 
species (Pf/Pan). Approximately three-quarters of RDT-
stocking outlets in Cambodia stocked Pf/Pv RDT (pub-
lic 81.0%, private 76.3%) and one-quarter stocked Pf/Pan 
(public 37.7%, private 24.7%). Almost all RDT-stocking 
outlets in the Lao PDR stocked Pf/Pv RDT (public 99.4%, 
private 98.9%). Similarly, outlets stocking RDT in Myan-
mar’s public sector almost exclusively stocked RDT that 
could detect Pf/Pv (96.3%), while 76.5% of private sector 
outlets stocked Pf/Pv RDT and 18.6% stocked Pf/Pan. 
All public and private RDT-stocking outlets in Thailand 
stocked Pf/Pan RDT.
Anti-malarial market share: volumes distributed in outlets 
with and without confirmatory testing
In Cambodia, 90% of all anti-malarials distributed were 
distributed by outlets that had confirmatory testing avail-
able (Fig. 6). This includes all anti-malarials distributed by 
public health facilities and most anti-malarials distributed 
by CHWs. Over half of all anti-malarial distribution was by 
outlets that did not have confirmatory testing available in 
the Lao PDR (54%) and Myanmar (59%). Anti-malarial dis-
tribution by outlets without confirmatory testing available 
occurred primarily in pharmacies in the Lao PDR, where 
45.1% of the total markets share was distributed through 
outlets without testing. In Myanmar, distribution of anti-
malarials without  confirmatory testing available was com-
mon across all private sector outlet types.
Private sector support and engagement
In all three countries with an authorized private sector, 
private health facilities and pharmacies more commonly 
received some form of support compared to other private 
sector outlet types, but some country differences were 
observed (Table 6). With regards to training and supervi-
sion, in Cambodia and the Lao PDR, over 20% reportedly 
received training on malaria diagnosis (Cambodia, 23.9%; 
the Lao PDR, 31.7%) or the NTGs (Cambodia, 22.2%; the 
Lao PDR, 22.0%). Less than 10% of providers in Myanmar 
*Drug stores do not exist in Myanmar
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reportedly received either training. Close to half of the 
providers in the Lao PDR (46.7%) reportedly received 
some form of supervisory or regulatory visit in the past 
12  months. This was lower in Myanmar and Cambodia 
(19.9 and 10.6%, respectively). In Myanmar, this supervi-
sion was most common among private for-profit facilities 
and general retailers.
In terms of access to subsidized commodities, almost 
40% of providers in the Lao PDR reported having 
received subsidized or free anti-malarials or RDT (anti-
malarials, 36.2%; RDT, 37.9%). In Cambodia, around 1 in 
4 providers reportedly received subsidized anti-malarials 
(26.9%) and this was most commonly reported by private 
for-profit facilities (40.1%) and pharmacies (52.1%) but 
also among itinerant drug vendors (15.0%).
Caseload data reporting was highest in the Lao PDR 
(41.9%), common among private for-profit facilities 
(65.1%) and pharmacies (55.4%) and negligible or zero 
among other outlet types. In Cambodia’s private sector, 
17.5%  of facilities  reportedly report caseload data, and 
while most common among private for-profit facilities 
(32.4%), also included pharmacies (17.2%), drug stores 
(8.2%), and itinerant drug vendors (5.9%). In Myanmar, 
private sector caseload reporting was reported among 
fewer than 10% of outlets and was most common among 
private for-profit facilities (40.3%).
Discussion
Findings from this multi-country study suggest that the 
private sector for malaria case management in Cambo-
dia, Myanmar, and the Lao PDR is generally in alignment 
with national regulations, treatment guidelines and qual-
ity-assurance standards. However, important gaps persist 
and pose a threat to national malaria control and elimina-
tion goals.
Anti-malarial availability among informal 
and unauthorized private-sector outlets
In 1995, Thailand banned the sale of anti-malarials in 
the private sector as a method of controlling the spread 
of drug resistant parasites. Of the 13,000 private-sector 
outlets screened during the Thailand survey, only 19 were 
found to be stocking anti-malarials. These results suggest 
that the long-standing private-sector ban on anti-malar-
ial sales in Thailand has been widely enforced.
The private-sector market composition was substantial 
in Cambodia, the Lao PDR, and Myanmar, where one-
third or more of anti-malarial service delivery points 
were found in the private sector. Unlike Myanmar, where 
all private-sector outlet types were authorized to test for 
and treat malaria, in Cambodia and the Lao PDR, drug 
stores, general retailers, and itinerant drug vendors were 
required to refer patients with fever to public-sector out-
lets, private health facilities, or pharmacies for appropri-
ate care [20]. However, nearly half of the private-sector 
providers in Cambodia and approximately one-quarter 
in the Lao PDR were unauthorized drug stores, gen-
eral retailers, or itinerant drug vendors, which typically 
lack formal ties to the public health system and national 
malaria surveillance systems [15]. Such outlets, there-
fore, pose a threat to case management according to 
NTGs.
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Almost half of the private-sector outlets in Cambodia 
were unauthorized outlets, which is of importance given 
national efforts to increase regulation of the informal pri-
vate sector as part of the country’s elimination plans. In 
2010, the Cambodian government created a new police 
force exclusively to impose a ban on private anti-malarial 
drug sellers. Previous ACTwatch outlet survey data show 
a substantial decline in the relative number of anti-malar-
ial stocking drug stores and general retailers since 2009, 
which has largely been attributed to increased regula-
tion of the private sector [4]. However, the current survey 
indicates that there are still a substantial number of unau-
thorized outlets carrying anti-malarials. This may reflect 
continued patient demand for case management services 
Table 6 Percent of private sector providers that reportedly received malaria case management training within the last 
year, supervision within the last year, subsidized anti-malarials and/or malaria RDT, and report caseload data
Providers in outlets that have malaria testing and/or treatment available on the day of the survey or in the past 3 months
a  Questions about subsidized anti-malarials and RDT were not asked in Myanmar
b  Drug stores do not exist in Myanmar
Private for- profit health 
facility
% (CI)
Pharmacy
% (CI)
Drug store
% (CI)
General retailer
% (CI)
Itinerant drug vendor
% (CI)
Private sector total
% (CI)
Cambodia N = 318 N = 99 N = 46 N = 39 N = 235 N = 737
 Training on malaria 
diagnosis
36.6 43.3 16.4 3.2 9.3 23.9
(29.3, 44.6) (31.9, 55.4) (7.8, 31.2) (0.7, 13.8) (6.3, 13.7) (19.5, 28.9)
 Training on NTGs 34.8 41.5 15.2 3.2 7.3 22.2
(27.1, 43.3) (31.0, 52.7) (6.8, 30.5) (0.7, 13.8) (4.7, 11.3) (17.8, 27.4)
 Supervision or regulatory 
visit
18.4 14.7 9.4 0.0 2.9 10.6
(13.8, 24.1) (7.6, 26.5) (2.5, 29.8) – (1.4, 5.8) (7.5, 14.7)
 Subsidized anti-malarials 37.9 52.9 12.2 0.0 14.3 26.9
(32.1, 44.1) (43.2, 62.4) (6.1, 22.9) – (10.3, 19.5) (23.0, 31.1)
 Subsidized RDT 40.1 52.1 27.8 0.0 15.0 29.0
(34.2, 46.2) (43.9, 60.2) (15.9, 44.1) – (10.6, 20.9) (25.0, 33.3)
 Report caseload data 32.4 17.2 8.2 0.0 5.9 17.5
(24.2, 41.9) (9.5, 29.3) (1.8, 30.1) – (3.0, 11.5) (12.1, 24.5)
Lao PDR N = 94 N = 330 N = 6 N = 30 N = 5 N = 465
 Training on malaria 
diagnosis
36.6 42.8 4.6 3.7 21.0 31.7
(25.5, 49.3) (33.1, 53.1) (0.6, 26.1) (0.6, 19.5) (2.9, 70.3) (23.9, 40.7)
 Training on NTGs 23.3 27.7 30.3 3.7 21.0 22.0
(16.4, 31.9) (21.0, 35.5) (6.1, 74.5) (0.6, 19.5) (2.9, 70.3) (16.7, 28.4)
 Supervision or regulatory 
visit
50.2 62.1 16.7 11.5 0.0 46.7
(37.9, 62.5) (50.4, 72.6) (3.7, 51.0) (5.7, 21.9) – (37.7, 56.0)
 Subsidized anti-malarials 41.8 50.4 0.0 2.5 0.0 36.2
(28.8, 56.1) (39.7, 61.0) – (0.4, 14.5) – (27.9, 45.3)
 Subsidized RDT 40.4 52.0 25.7 2.5 0.0 37.9
(26.7, 55.9) (40.7, 63.0) (4.1, 73.5) (0.4, 14.5) – (29.2, 47.4)
 Report caseload data 65.1 54.5 0.0 2.5 0.0 41.9
(53.4, 75.2) (42.7, 65.9) – (0.4, 14.5) – (33.2, 51.1)
Myanmara N = 354 N = 576 N/Ab N = 1487 N = 508 N = 2925
 Training on malaria 
diagnosis
22.6 12.1 – 3.2 4.4 8.0
(17.4, 27.7) (7.1, 17.0) (1.4, 5.0) (2.3, 6.4) (5.9, 10.2)
 Training on NTGs 23.6 9.3 – 6.4 6.7 9.4
(18.1, 29.1) (4.9, 13.7) (3.6, 9.3) (3.4, 9.9) (6.9, 11.8)
 Supervision or regulatory 
visit
32.0 16.7 – 19.2 12.5 19.9
(25.5, 38.6) (12.7, 20.8) (16.0, 22.3) (8.6, 16.3) (17.1, 22.7)
 Report caseload data 40.3 4.7 – 2.4 7.7 9.4
(31.0, 49.6) (2.6, 6.9) (1.0, 3.8) (4.3, 11.1) (6.7, 12.1)
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across different outlet types as well as motivation among 
unauthorized providers to provide services to meet the 
demand. This may also reflect inadequate capacity of 
inspection and judiciary agencies, and a lack of resources 
to implement routine inspections as evidenced by other 
research [21, 22]. A review by Montagu and Goodman 
regarding the regulation of the private sector in devel-
oping countries has shown that regulatory approaches 
face persistent challenges [23]. Montagu and Goodman 
conclude that increased regulatory capacity should be 
the medium-term and long-term priority for develop-
ing countries and that short-term attention should be 
focused on interventions that encourage private provid-
ers to improve the quality and coverage of their care, thus 
allowing them to advance their own financial interests.
Approximately two-thirds of the unlicensed outlets in 
Cambodia were itinerant drug vendors. Although more 
research is needed to better understand the role itiner-
ant drug vendors play, the current survey indicates that 
these providers were an important community-level 
anti-malarial access point [24]. In Cambodia there is evi-
dence that itinerant drug vendors often have some sort 
of health qualification and have in the past been, or are 
currently affiliated with, public or private health facili-
ties or pharmacies [25]. As such, it may be possible to 
formally engage these providers through private-sector 
mechanisms. One option would be to integrate these 
providers into the formal health system through training, 
supervision, business incentives, and accreditation [26]. 
Several malaria-endemic countries which have incorpo-
rated itinerant drug vendors into the private sector have 
documented improvements in provider knowledge and 
performance [27]. This option further speaks to the rec-
ommendations by Montagu and Goodman that would 
allow for the improvement of the quality and coverage of 
private sector care, while advancing providers’ own finan-
cial interests. The integration of itinerant drug vendors 
into the formal private sector could be operationalized 
through Cambodia’s PPM programme by incorporating 
these providers into the existing strategy. As the cur-
rent PPM mechanism aims to train private providers on 
appropriate malaria diagnosis, treatment, and referral 
procedures, this would allow for a more regulated inclu-
sion of the private sector in malaria case management 
while still adhering to national guidelines [28].
Myanmar represents a unique situation in that a large 
majority of the private sector comprises itinerant drug 
vendors and general retailers but in contrast to other 
GMS countries, these outlet types are permitted to test 
for and treat malaria. Private-sector strategies through 
the AMTR project in the Eastern part of the country have 
leveraged these providers to increase access to quality-
assured, subsidized ACT medicines, and more recently 
RDTs [3, 29]. Other supportive strategies have included 
engaging with general retailers and itinerant drug ven-
dors through product promoters and provider behaviour 
change communication, and several positive outcomes 
of these strategies have been documented [3]. How-
ever, while these providers have received access to sub-
sidized commodities and supportive interventions, they 
are not currently part of a national strategy that actively 
registers, trains and supervises these outlets. Further-
more, most private-sector engagement has historically 
taken place in the Eastern part of the country. Given this, 
Myanmar’s findings do pose some challenges in the con-
text of elimination strategies. In the absence of formally 
regulating these private-sector outlets, it will be chal-
lenging to routinely monitor and supervise providers, 
or obtain malaria surveillance data from them, which is 
a cornerstone of elimination strategies [15]. For example, 
data from Myanmar’s survey shows that only 3% of gen-
eral retailers provide any sort of caseload data. The extent 
to which these types of outlets can be part of the broader 
elimination efforts, in the absence on national strategies 
to regulate, train and supervise these providers, needs to 
be determined. Initiatives from neighbouring countries 
in Cambodia and the Lao PDR, to formally incorporate 
such outlets into a programme similar to PPM will be 
useful to draw upon.
Alignment of anti-malarial availability and distribution 
with national guidelines
According to NTGs, malaria cases confirmed with 
blood testing should be treated with first-line drugs. 
Nearly three-quarters of anti-malarial stocking private-
sector outlets stocked P. falciparum and P. vivax first-
line treatments for uncomplicated malaria in Cambodia 
and approximately half of private-sector outlets in the 
Lao PDR and Myanmar. In all countries, availability of 
P. falciparum and P. vivax first-line treatment was high-
est in private for-profit health facilities and pharmacies 
compared to availability in drug stores, general retailers, 
and itinerant drug vendors. The majority of anti-malar-
ials distributed were P. falciparum and P. vivax first-line 
treatments in Cambodia (~85%) and Myanmar (~70%), 
however, the market share for first-line treatments in the 
private sector was very low in the Lao PDR (<10%). These 
results suggest that in Cambodia and Myanmar, most 
of the anti-malarial distribution was in accordance with 
NTGs, but there are notable gaps in the Lao PDR’s pri-
vate sector.
In the GMS, both P. falciparum and P. vivax malaria 
account for a significant proportion of clinical cases [14]. 
Although first-line treatment for uncomplicated P. falci-
parum and P. vivax malaria is the same in some countries 
(e.g. Cambodia, the Lao PDR), second-line treatment and 
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treatment for specific populations (e.g. pregnant women) 
differs, necessitating RDT with the capability to differ-
entially diagnose P. falciparum from P. vivax malaria. 
Almost all RDT audited during the outlet surveys in 
Cambodia, the Lao PDR, Myanmar, and Thailand were 
Pf/Pv or Pf/Pan RDT. The small number of RDT audited 
in Cambodia, the Lao PDR, and Myanmar that could 
only detect P. falciparum malaria were manufactured by 
Standard Diagnostics  (Bioline®) or Orchid Biomedical 
Systems  (Paracheck®). These results suggest that where 
RDT testing is available and implemented, providers are 
able to identify parasite species to facilitate treatment 
according to treatment guidelines.
Misalignment of anti-malarial availability and distribution 
with national guidelines
Within the GMS, adherence to first-line guidelines is 
essential. NTGs are regularly updated to reflect the lat-
est evidence on which anti-malarials remain efficacious 
for parasite clearance [1]. This is perhaps most notable in 
Cambodia, which has seen several revisions to the first-
line treatment over the past decade in response to drug 
resistant parasites, though recent changes to the NTGs 
have been observed across all the study countries. The 
continued availability and use of medicines that are not 
in the NTGs, or misuse or inappropriate use of second-
line treatments in the private sector, not only threatens 
effective malaria control, but also national and regional 
elimination strategies and goals.
Private‑sector second‑line treatment
Second-line treatment should be utilized only after treat-
ment failure with the first-line drug. Therefore, the avail-
ability of the second-line drug should be limited to public 
health facilities equipped to detect and manage first-line 
treatment failure. Second-line treatment is not expected 
to be available within private-sector outlets, especially 
pharmacies, drug stores, general retailers, and itinerant 
drug vendors that are not trained or authorized to man-
age treatment failure.
Second-line treatment availability in the private sec-
tor was high in the Lao PDR (~75%), low in Myanmar 
(~20%), and negligible in Cambodia (<1%). In Myanmar, 
second-line treatment accounted for 4% of private-sec-
tor market share, whereas in the Lao PDR, second-line 
treatment distribution dominated the market, account-
ing for close to 60% of overall market share and most of 
private-sector market share. Such high second-line 
treatment market share, despite moderate private sector 
availability of first-line P. falciparum and P. vivax treat-
ment, suggests that factors other than availability are 
driving private-sector anti-malarial distribution in the 
Lao PDR.
Nearly all second-line treatment distributed in the Lao 
PDR was chloroquine, which is indicated for treatment of 
P. vivax malaria after AL treatment failure. Chloroquine 
should only be stocked at health facilities with the nec-
essary equipment and skilled staff required to detect and 
manage treatment failure, however, in the Lao PDR, more 
than three-quarters of second-line treatment was dis-
tributed at pharmacies. This finding suggests that chlo-
roquine was being used inappropriately to treat patients 
presenting for the first time with signs and symptoms of 
malaria. Furthermore, it is estimated that close to two-
thirds of malaria cases in the Lao PDR are P. falciparum 
infections [14], which suggests chloroquine could also 
have been used to treat patients indiscriminately who 
may have P. falciparum malaria, for which chloroquine 
has been shown to have high treatment failure rates [30].
Regulation and removal of chloroquine from the 
Lao PDR private-sector outlets is urgently needed to 
facilitate sale and use of first-line P. falciparum and P. 
vivax treatment. Removing this product could be com-
plex given that the majority of chloroquine distributed 
in the Lao PDR was  Maraquine® brand, manufactured 
locally by CBF Pharma, and included in the national list 
of registered medicines [25]. Removing a locally manu-
factured product from the market could have potential 
economic repercussions or provoke political sensitivi-
ties. As it is unlikely that local manufacturers will have 
the technical expertise, raw materials, quality standards, 
and production and laboratory equipment to produce 
the first-line ACT treatment [31] or to receive GMP 
status to enable purchase of the medicines using inter-
national donor funds, other compensation or incen-
tive schemes may be necessary to halt the production 
of locally manufactured chloroquine. While some may 
argue that there are opportunities to work with local 
manufacturers to support the introduction of GMP and 
internal quality assurance in local pharmaceutical facto-
ries [32], others have concluded that investment to pro-
mote local manufacturing of medicines could be better 
used to promote health infrastructure [33]. Further 
attention is needed to actively engage with the manu-
facturer and advocate for halting the local distribution 
of this product.
Private‑sector treatment that is not in the NTGs
The availability and distribution of treatments that are 
not in the NTGs should be carefully assessed, particu-
larly in the context of elimination strategies and goals. 
Treatments that are not included in the NTGs, especially 
oral artemisinin monotherapy, not only pose a threat to 
patient health and safety and have the potential to delay 
parasite clearance and drive drug resistance [34, 35], 
but also pose a threat to effective malaria control and 
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elimination goals. NTGs are regularly updated to reflect 
the latest evidence on which anti-malarials remain effi-
cacious for parasite clearance, and thus it is of utmost 
importance that patients and providers adhere to these 
guidelines.
Availability and market share of treatment not in the 
NTGs differed by country and outlet type. In Cambodia 
and Myanmar, approximately 1 in 3 private-sector out-
lets stocked treatment not in the NTGs, accounting for 
15 and 25% of private-sector market share, respectively. 
In Cambodia, a large majority of this treatment was chlo-
roquine, while in Myanmar, treatment not in the NTGs 
was predominantly oral artemisinin monotherapy. The 
majority of these treatments in Cambodia and Myanmar 
were stocked by general retailers and itinerant drug ven-
dors. Availability of treatment not in the NTGs was lower 
in the Lao PDR but still notable, with more than one in 
seven private-sector outlets stocking treatment that was 
not in the NTGs.
In Myanmar, 14 unique brands of oral artemisinin 
monotherapy were audited, primarily at general retail-
ers, pharmacies, and itinerant drug vendors. Unbranded 
artesunate tablets manufactured by  Mediplantex® (Viet-
nam) accounted for nearly three-quarters of all anti-
malarials not included in the NTGs. While several 
strategies have been in place to remove this medicine 
from the market, including the aforementioned AMTR 
project and a 2012 ban on oral artemisinin monotherapy, 
availability and market share was widespread. Reasons 
for the widespread availability and distribution may be 
in part attributed to an incomplete ban on oral AMT, 
which permits the continued importation of this medi-
cine from manufacturers for up to 5 years from when the 
ban was first implemented. Several strategies are urgently 
needed to ensure the removal of this medicine, includ-
ing enforcement of the ban. These could include active 
efforts to remove the product from the shelves and/or 
communications campaigns to promote provider compli-
ance with the ban [4].
In Cambodia, the majority of audited anti-malarials 
that were not in the NTGs were either non-FDC ASMQ, 
artemisinin piperaquine, or chloroquine tablets, and of 
the nine specific brands audited, none were included in 
the country’s drug registry [24]. In 2009, chloroquine was 
the first-line P. vivax malaria treatment in Cambodia, but 
in 2011, first-line treatment changed to DHA PPQ or 
ASMQ after evidence of chloroquine treatment failure 
[36]. Audited chloroquine products included  Nitaquin® 
manufactured by Utopian and unbranded chloroquine 
manufactured by Acdhon, both of which were manu-
factured in Thailand. The availability of chloroquine 
points to the need for tighter regulation, registration of 
anti-malarials, and stricter importation laws, including 
tightened importation controls, to ensure these medi-
cines are removed from the market. Measures may also 
include passing a law to ban chloroquine from the mar-
ket, similar to the one passed for oral artemisinin mono-
therapy, which has been a successful in Cambodia [4].
The current PPM programmes implemented in Cam-
bodia and the Lao PDR provide an opportunity and a 
strong foundation to scale up access to first-line treat-
ments in the private sector and remove any unwanted 
medicines from the shelves. Similar accreditation pro-
grammes that combine training, business incentives, 
supervision, and regulatory enforcement have been suc-
cessful at improving the quality of medicines and services 
provided by the private sector [26]. On-going efforts 
could be supported with mystery shoppers to check that 
providers are only stocking first-line anti-malarials, and 
be complemented by increased supervision and regula-
tion to enforce removal of NTG anti-malarials from the 
market. In fact, a targeted private-sector intervention in 
the Lao PDR involving inspections of the pharmacies, 
provision of information on essential medicines, and 
distribution of malaria case management documents 
found marked improvements in the availability of essen-
tial medicines and concluded that these activities were 
an important factor behind the service quality improve-
ments [37].
Malaria diagnosis
Availability of any test and market share
Across outlet types and countries, private-sector avail-
ability of confirmatory testing among anti-malarial stock-
ing outlets was generally moderate. However, gaps in 
testing availability were observed among outlets author-
ized to test, such as private-for-profit health facilities and 
pharmacies across all countries. In Myanmar, availability 
was particularly low. Closing gaps in availability of test-
ing and first-line treatment in private sectors across the 
GMS is needed to ensure that people seeking treatment 
in the private sector are managed according to national 
guidelines.
Outlet survey methods do not allow for determining 
whether anti-malarials were distributed for confirmed or 
unconfirmed cases. However, the audit methodology can 
be used to summarize what proportion of anti-malarials 
distributed were dispensed by outlets with testing avail-
able to the patient. In Cambodia, anti-malarial distribu-
tion in both the public and private sectors was typically 
occurring in outlets that have confirmatory testing avail-
able, which is promising and suggests that testing is at 
least available to patients prior to being administered 
treatment. However, in the Lao PDR and Myanmar, 
the private sector appears to be a source for presump-
tive treatment. Most anti-malarials were distributed by 
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private-sector outlets without confirmatory testing avail-
able. This is of particular concern in Myanmar, given that 
patients should be given different first-line treatment 
regimens according to whether or not they test positive 
for P. falciparum or P. vivax. As most anti-malarial distri-
bution occurred through outlets that do not have testing 
available suggests that presumptive treatment is rife. Fur-
thermore, while availability of first-line treatments was 
high in Myanmar, patients were unlikely to be treated 
correctly in the absence of confirmatory testing. As the 
NTGs are different for P. falciparum and P. vivax malaria, 
adhering to national malaria treatment guidelines was 
inherently impossible for most private-sector provid-
ers in the absence of confirmatory testing. Moving for-
ward, closing these gaps will be key. Increased coverage 
of malaria testing   in  the private sector will not only be 
important to ensure appropriate treatment and rational 
drug use, but also to track all confirmed cases towards a 
complete national surveillance system.
RDT availability with global quality‑assured standards
The Global Fund to fight AIDS, Tuberculosis and Malaria 
(GFATM) periodically publishes a list of quality-assured 
RDT that are recommended for use after technical evalu-
ation by the WHO Malaria RDT Testing programme 
and/or WHO Prequalification of Diagnostics programme 
[38]. Although RDT on this list have been shown to be 
accurate and reliable, inclusion does not preclude manu-
facturing quality failures or degradation due to prolonged 
storage or extreme conditions. Furthermore, RDT that 
have not been submitted for testing or prequalification 
may still meet regulatory standards and are eligible for 
procurement by GF principle recipients. Nonetheless, the 
GF quality assurance status is viewed as a global standard 
for RDT quality.
Most RDT-stocking outlets were stocking quality-
assured RDT. However, non quality-assured RDT were 
available in 1 in 4 private-sector outlets in Cambodia 
and 1 in 5  private-sector outlets in Myanmar. Assured 
product quality is important given the variation in RDT 
brand performance. In the context of malaria elimina-
tion settings, it is imperative that future procurement 
of RDT includes only quality-assured products. Non 
quality-assured RDT can also leave providers uncertain 
about the reliability of results, which in turn can lead to 
the over-use of malaria medicines.  However, with over 
60 manufacturers of malaria RDT, this profusion can 
make it difficult for national malaria control programmes 
to determine which test or tests to purchase [39]. Con-
tinued guidance will be required to assist private-sector 
procurement services and private importers to take into 
account the quality-assurance status of RDTs when mak-
ing purchasing and regulatory decisions [40].
Coverage of private sector engagement and support
Key strategies to ensure that private-sector providers are 
contributing to national goals have included training, 
supervision, providing access to free or subsidized com-
modities, and ensuring that the private sector contributes 
caseload data to national surveillance systems. As previ-
ously discussed, these strategies are being implemented 
in various forms across the region, including the PPM 
programmes in Cambodia and the Lao PDR. In these 
countries, private-sector engagement targets providers 
in private for-profit health facilities and pharmacies. In 
Myanmar, various strategies are targeted to engage all 
private sector outlet types, including general retailers and 
itinerant drug vendors.
Results from these outlet surveys show that strate-
gies implemented in each country were not reaching the 
majority of private providers. Fewer than half of provid-
ers reported receiving any sort of supervisory or regula-
tory visit within the past year and/or reporting malaria 
caseload data to government or non-governmental 
organizations. Less than half of the private providers in 
Cambodia, the Lao PDR reported access to subsidized 
ACT medicines and/or RDT, despite efforts across all 
three countries to increase access to subsidized anti-
malarials through national private-sector distribu-
tion schemes. Supervision and caseload reporting were 
highest in the Lao PDR and were the result of the cur-
rent PPM programme. The results from this study point 
to the need to scale-up up current PPM programmes in 
these countries, to include more licensed providers in the 
scheme as a means to ensure universal coverage of testing 
and treatment and increased private-sector regulation. 
Of promise is that national strategic plans for malaria 
elimination in both countries include scale-up and 
expansion of the PPM programme [20, 41]. These results 
may also serve as a baseline for the much-needed work of 
engaging private providers to ensure appropriate malaria 
case management and surveillance.
Several lessons can be taken from other pilot initia-
tives implemented to leverage the private sector in order 
to improve access to anti-malarials and RDT to improve 
malaria case management. Perhaps most noteworthy 
was the affordable medicines facility malaria (AMFm), 
which was designed to increase access to affordable qual-
ity-assured ACT medicines in both the public and pri-
vate sectors in eight countries. During the AMFm pilot, 
manufacturers were provided copayments to subsidize 
wholesale quality-assured ACT medicine prices, and sup-
portive interventions, including provider training and 
behaviour change communications were implemented. 
An evaluation of the AMFm pilot showed substantial 
increases in availability and market share for first-line 
treatment for uncomplicated malaria in most countries 
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[42]. This was attributed to the subsidy but also several 
supportive interventions designed to create awareness 
and demand among patients and providers. Future strat-
egies in the GMS designed to maximize coverage of the 
first-line treatment may want to consider scaling up sup-
portive interventions to drive provider awareness for 
testing and first-line anti-malarial medicines as well as 
improving access to subsidized first-line treatments.
Improved private-sector malaria case reporting will also 
be important not only so that patients can be tracked and 
managed appropriately but also to ensure complete and 
timely case reporting [1]. This is especially important in 
elimination settings such as the GMS, where all cases must 
be tracked and investigated. Results from this study indi-
cate that the majority of private-sector providers engaging 
in malaria testing and treatment do not provide malaria 
caseload data to a government authority or non-govern-
mental organization across countries. Several challenges 
have been identified with incorporating the private sector 
into malaria surveillance systems [15]. Several initiatives 
are underway in Cambodia, the Lao PDR, and Myanmar 
to improve private-sector case management practices and 
ensure caseload reporting as part of the GMS Elimination 
of Malaria through Surveillance (GEMS) project in Cam-
bodia, the Lao PDR, Myanmar, and Vietnam. The GEMS 
project includes provider training and supervision and 
strategies to strengthen private sector surveillance [43]. 
Caseload data from the private sector will be integrated 
with public-sector data to provide national programmes 
with a more complete picture of malaria burden and infor-
mation to respond to all detected cases.
Strengths and limitations
The ACTwatch project has conducted approximately 50 
outlet surveys in 12 countries in Africa and Asia. The 
outlet survey methodology is rigorous and uses stand-
ardized methods and data collection tools across coun-
tries and over time. The use of a full census of all outlets 
with the potential to stock anti-malarials and/or malaria 
RDT allows for a unique analysis of the total malaria 
testing and treatment market. The surveys conducted 
in the GMS provide useful information that can be used 
to support national policy towards malaria control and 
elimination.
Several limitations should be considered when inter-
preting ACTwatch outlet survey results [16, 19], as with 
other medicine surveys [44]. This includes the cross-
sectional nature of the surveys, potentially biased or 
misreported information, and challenges related to 
standardizing anti-malarial volumes and prices for prod-
ucts with different active ingredients and formulations. 
Providers may hide anti-malarials, especially providers 
who are not authorized to provide testing and treatment 
(e.g. general retailers), or providers who stock banned 
anti-malarials that are illegal to distribute (e.g. oral arte-
misinin monotherapy). This may be more common in 
malaria elimination settings where more resources are 
earmarked for enforcement of regulation [44]. Mystery 
client surveys may be an important source of data to tri-
angulate results from the outlet surveys, particularly with 
respect to stocking practices of banned products when 
total market data is not needed. Finally, the outlet surveys 
conducted in the GMS were designed to generate results 
for key indicators including malaria testing and treatment 
availability, market share, and private-sector engagement 
and support and were not intended to evaluate specific 
programmes such as the PPM initiatives in the Lao PDR 
and Cambodia. Specific study designs with appropriate 
sampling techniques would be needed to determine the 
effectiveness and impact of these interventions.
Conclusion
Findings from this multi-country study suggest that the 
private sector for malaria case management in Cambo-
dia, Myanmar and the Lao PDR is generally in alignment 
with national regulations, treatment guidelines, and RDT 
quality-assurance standards. However, important gaps 
persist and pose a threat to national malaria control and 
elimination goals. In 2015, there was still a substantial 
amount of treatment not included in the NTGs stocked 
and distributed in Cambodia and Myanmar, as well as 
inappropriately high distribution of second-line P. vivax 
malaria treatment in the Lao PDR. As malaria elimina-
tion efforts intensify, it will be important to enforce 
removal of these products from private-sector outlets 
and to ensure only authorized outlets are providing 
malaria testing and treatment services. Decisions about 
whether or not informal providers warrant inclusion into 
the formal health system need to be made. Private-sector 
engagement was inadequate in Cambodia, the Lao PDR, 
and Myanmar. Increased engagement has the potential 
to improve malaria case management, readiness, and 
case reporting, and is thus critical for continued progress 
towards malaria elimination goals in the GMS.
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